Cefuroxime Capsules

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor.

The main ingredient of this product is cefradine, and its chemical name is (6R,7R)-7[(R)-2-amino-2-(1,4-cyclohexenyl)acetylamino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid.

The content of this product is white to off-white or light yellow powder or granules.

It is suitable for acute pharyngitis, tonsillitis, otitis media, bronchitis, pneumonia and other respiratory tract infections, urogenital tract infections and skin and soft tissue infections caused by sensitive bacteria. This product is an oral preparation and should not be used for severe infections.

Oral administration, the usual dosage for adults is 0.25-0.5g once, once every 6 hours. For patients with more serious infections, the dosage can be increased to 1g once, but the total dosage per day should not exceed 4g. The usual dosage for children is 6.25-12.5mg/kg once, once every 6 hours, according to body weight.

The adverse reactions of this product are mild and the incidence is low, about 6%. Gastrointestinal reactions such as nausea, vomiting, diarrhea, and upper abdominal discomfort are more common. The incidence of drug rash is about 1% to 3%. Pseudomembranous colitis, eosinophilia, positive reaction to direct Coombs test, peripheral blood leukocytopenia and neutrophil granulocyte reduction are seen in individual patients. A small number of patients may experience temporary increase in blood urea nitrogen, serum aminotransferase, and serum alkaline phosphatase.

This product is contraindicated in patients who are allergic to cephalosporins or have a history of anaphylactic shock or immediate reaction to penicillin.

Precautions for children: Adverse reactions reported after domestic marketing may cause hematuria when using this product. Children are susceptible to the disease. Children should use this product with caution and under monitoring. Precautions for pregnancy and lactation: This product can enter the fetal blood circulation through the placental barrier and can also enter breast milk. Pregnant and lactating women should use it with caution. Precautions for the elderly: Not yet clear.

1. Cephalosporins can delay the excretion of phenytoin sodium in the renal tubules. 2. Phenylbutazone combined with cephalosporin antibiotics can increase renal toxicity. 3. Combined with strong diuretics, it can increase renal toxicity. 4. Combined with mecillinam, it has a synergistic effect on gram-negative bacteria such as Escherichia coli and Salmonella. 5. Probenecid can delay the renal excretion of this product.

Store at room temperature away from light. Valid for 2 years.

Calculated as C16H19N3O4S 0.25g

24 months.

Beijing Jingfeng Pharmaceutical Co., Ltd.

• Founded in:

  2002-03-06

• Address:

  Building 1, Building 9-10, Building 12-13, No. 21, Xiangrui Street, Daxing Biomedicine Industry Base, Zhongguancun Science Park, Daxing District, Beijing

• Tax NO.:

  91110000736469100Q

• Registered Funds:

  475.3425 million yuan

• Website:

  Log in to view

• Email:

  Log in to view